Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
暂无分享,去创建一个
Bruce A. Johnson | J. Berger | D. Moller | Gaochao Zhou | J. Ventre | T. Doebber | A. Elbrecht | R. Surwit | Bei B. Zhang | R. Mosley | K. Macnaul | L. Kelly | C. Biswas | A. Petro | M. Tanen | A. Adams | Neelam Sharma | G. M. Thompson | K. Richards | Mona Parikh | Bruce A. Johnson
[1] Ansuman Bagchi,et al. Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated Receptor-γ Agonists. , 2002, Endocrinology.
[2] H. Lebovitz,et al. Differentiating members of the thiazolidinedione class: a focus on safety , 2002, Diabetes/metabolism research and reviews.
[3] E. Wooltorton. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[4] L. Rossetti,et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. , 2001, The Journal of clinical investigation.
[5] Y. Terauchi,et al. The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.
[6] J. Auwerx,et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.
[7] M. Butterworth,et al. Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus. , 2001, The Journal of endocrinology.
[8] M. Hanefeld,et al. Safety profile of pioglitazone. , 2001, International journal of clinical practice. Supplement.
[9] A. Saltiel. New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes , 2001, Cell.
[10] H. Lodish,et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] Neil J McKenna,et al. From ligand to response: generating diversity in nuclear receptor coregulator function , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[12] J. Bilakovics,et al. A Selective Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Modulator Blocks Adipocyte Differentiation but Stimulates Glucose Uptake in 3T3-L1 Adipocytes , 2000 .
[13] K. Eguchi,et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. , 2000, Diabetes care.
[14] R G Smith,et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.
[15] S. A. Parent,et al. A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus , 2000, Molecular and Cellular Endocrinology.
[16] Kristina Schoonjans,et al. Thiazolidinediones: an update , 2000, The Lancet.
[17] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[18] B. Spiegelman,et al. A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor γ Inhibits Adipocyte Differentiation* , 2000, The Journal of Biological Chemistry.
[19] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[20] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[21] Satoshi Tanaka,et al. PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .
[22] B. Spiegelman,et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .
[23] J. Lehmann,et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] C. Glass,et al. Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.
[25] J. Berger,et al. L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ , 1999, The Journal of Biological Chemistry.
[26] Margaret S. Wu,et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.
[27] M. Lazar,et al. Mechanisms by which Thiazolidinediones Enhance Insulin Action , 1999, Trends in Endocrinology & Metabolism.
[28] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. , 1998, Journal of medicinal chemistry.
[29] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[30] K. Umesono,et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.
[31] W. Wahli,et al. Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.
[32] J. Olefsky,et al. Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.
[33] B. Spiegelman,et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.
[34] M. D. Leibowitz,et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.
[35] R. Stein,et al. Determinants of promoter-specific activity by glucocorticoid receptor. , 1996, Molecular endocrinology.
[36] M. D. Leibowitz,et al. Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .
[37] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[38] B. Katzenellenbogen,et al. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.
[39] M. Billeter,et al. MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.
[40] J. Pike,et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.
[41] J. Rodin,et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. , 1995, Metabolism: clinical and experimental.
[42] J. Berger,et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. , 1995, Endocrinology.
[43] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[44] M. Feinglos,et al. Diet-Induced Type II Diabetes in C57BL/6J Mice , 1988, Diabetes.
[45] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[46] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[47] D. Moller,et al. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. , 2001, Advances in protein chemistry.
[48] L. Sorbera,et al. ROSIGLITAZONE MALEATE : PROP INNM , 1998 .
[49] D. Lockhart,et al. Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.
[50] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[51] S. Horwitz,et al. Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.
[52] J. Flatt,et al. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. , 1985, International journal of obesity.